Tecar terapija - Company finances
|
EUR
|
2022
From: 2022-09-26
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 24,107 | 60,576 | 78,605 | 57,580 |
| Profit before tax | 20,544 | 912 | 4,342 | -14,508 |
| Net profit | 20,544 | 866 | 4,125 | -14,508 |
| Equity | 20,544 | 21,410 | 25,535 | 11,027 |
| Liabilities | 1,213 | 31,703 | 30,209 | 157 |
| Non-current assets | 0 | 0 | 0 | 0 |
| Current assets | 21,757 | 53,113 | 55,744 | 11,184 |
| Total assets | 21,757 | 53,113 | 55,744 | 11,184 |
|
Taxes paid
|
||||
| STI taxes | - | 1,587 | 856 | 1,794 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +151.3% | +29.8% | -26.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 94.4% | 1.6% | 7.4% | -129.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 4.0% | 16.2% | -131.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 85.2% | 1.4% | 5.2% | -25.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 85.2% | 1.5% | 5.5% | -25.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 1.5 | 1.2 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 12,054 | 24,230 | 36,279 | 34,547 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Tecar terapija - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-06-16 | 2023-07-02 | 0.02 |
| 2023-05-16 | 2023-05-31 | 0.02 |
| 2023-05-02 | 2023-05-03 | 0.02 |
| 2023-04-25 | 2023-04-28 | 0.02 |
| 2023-03-16 | 2023-03-19 | 13.10 |
Tecar terapija - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-10-13 | 2025-10-18 | 0.02 |
| 2025-10-02 | 2025-10-08 | 0.02 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Tecar terapija, MB (code 306136017) is a Lithuanian small partnership engaged in physiotherapy activities. In 2025, the company generated revenue of €57.6K, down 26.8% year on year and 5.0% compared with 2023. Profitability weakened sharply after a stronger 2024: net profit fell to a loss of €14.5K in 2025 from a profit of €4.1K in 2024 and €866 in 2023. The 2025 profit margin was -25.2%, indicating that costs and/or one-off items outweighed sales during the year. The balance sheet also contracted materially. Total assets decreased to €11.2K from €55.7K a year earlier, while equity fell to €11.0K and liabilities were only €157. The company therefore ended 2025 with a very high equity ratio of 98.6% and a very low debt-to-equity level of 0.01, but return indicators were negative due to the loss and the smaller asset base. Asset turnover remained high at 5.15x, and revenue per employee was €57.6K.